|
|
|
|
Hello again Members,
We’re asking all of you to please turn your attention to MEDH.
We’re alerting this low float play as real possible high double-digit winner.
MEDH is no stranger to momentum surges as it’s been in the dollar range multiple times in its past.
Its current technical setup and charming low float gives plenty of reason to believe that that time to climb might be starting now.
Less than two weeks ago, MEDH announced it is in the process of becoming licensed as a Wholesale Distributor of Pharmaceuticals in the state of Alabama. As a result, the company has also entered into an Exclusive Marketing Agreement with B&B Consulting whose sales exceeded over $7M dollars in pharmaceutical sales in 2015. Mr. Hiltz, Managing Member of B&B Consulting has agreed to oversee the company’s pharmaceutical sales division. Mr. Hiltz stated “I am excited to join MedX Holdings, I believe that the combination of a public company and pharmaceutical sales just makes sense.”
In addition, MEDH has also secured an agreement with one of the largest FDA Manufacturers in the United States. Their first product that has been approved to sell is a 5% Lidocaine Ointment 50g jar. Negotiated price allows the company to have very competitive pricing to offer B&B’s current list of clients. 5% Lidocaine is a highly sought after analgesic ointment for the purpose of reducing and controlling pain. This comes at a time when the nation is riveting over the rising deaths occurring in epidemic proportion all resulting from the overuse of oral prescription pain medication. As a result, Physicians and other medical professionals are being forced to look at alternative solutions when treating pain.
Kathleen Roberton CEO of MedX Holdings stated, “It makes perfect sense to enter into Pharmaceutical and Nutraceutical sales as we build our portfolio of medial businesses. This will allow our company to produce its own revenue without being a burden to our acquisitions which add tangilble asset based value”.
More on that news release here.
Just last week, MEDH announced Mr. Charles Yelton R.Ph has joined the team as Vice President in charge of Nutraceutical and Pharmaceutical Development. In addition to this position as a licensed pharmacist, he will also serve as our Certified Designated Representative. Mr. Yelton has been a licensed pharmacist for over 39 years. He previously owned Carpenter Dent Drugs where he successfully grew this business from $146k to over $1.2M annually. After 23 years, he sold this business and went to work as a pharmacist for a major retail chain; he has worked in over 115 pharmacies throughout Kentucky and Alabama. Mr. Yelton was also the creator of Pain Doctor, an external OTC analgesic for pain distributed by ABC Pharmaceuticals.
Ms. Roberton, CEO commented: “we are very pleased to have Mr. Yelton join our team, I have personally had the pleasure of knowing him and his integrity for almost 10 years. Mr. Yelton’s experience and knowledge both as a licensed pharmacist and owner of ABC Pharmaceuticals is exactly what we needed to move forward as a licensed wholesale distributor of pharmaceuticals in many states”
Charles Yelton R.Ph, offered: “I am excited to join this talented MedX Holdings team. Together, we have the potential to create extreme dynamic sales growth very quickly. We are working with one the top pharmaceutical manufactures who holds over 105 ANDA’s which allows us to expand our projected RX lines and OTC lines very quickly.”
Their recent licensing update in that same news release updated that MEDH is in the final stages of securing a warehouse/office space in the state of Alabama as well as in the state of Florida. They will be licensed as a Wholesale Distributor of Pharmaceuticals in Alabama where Mr. Yelton works and is currently licensed. In Florida, they will ship directly to a Third Party Logistic partner who will legally ship to all of their clients in Florida. A Third Party Logistic Warehouse represents the fastest path for MedX to legally sell in the state of Florida. A 3PL does not manufacture the products, take title to own the products nor has anything to do with selling the products. Their partner will simply take possession, repackage if necessary, and then ship directly to the company’s clients.
BUSINESS SUMMARY
(MEDH - MedX Holdings, Inc.)
http://www.medxholdings.com/
MedX Holdings, Inc. or MEDH targets the acquisitions of undervalued, turnaround medical related businesses along with products and services that benefit our partners. MEDH’s mission is to provide a new form of governance enabling medical related businesses and product driven partners to take advantage of the power of a public company without losing management expertise. MEDH is introducing, Collaborative Profit, an innovative approach that allows each acquisition to become a stand-alone subsidiary with all the advantage and power of public company while keeping their independent management control. This unique diversified platform, designed by MEDH, offers protection for both the investor and the subsidiary. It provides acquisitions the ability to raise capital and offers investors the assurance that their investment is at low risk. The concept behind Collaborative Profit is to be mutually beneficial to all parties while leaving the control of the small business in the hands of the business owner. A management agreement transfers the rights and privileges that were in place prior to acquisition, back to the business owner. Essentially, the operations, accounts and administrative practices are in the hands of the business owner after the acquisition while MEDH manages the public company and over sees all management. Collaboration begins at the grassroots level. From the executives that run MedX Holdings down to respected consultants that serve the company, MEDH has seasoned professionals in the Healthcare Sector and veterans in medical management, sales and practice with over 35 years of experience.
MARKET OUTLOOK
Promising news for the future was found in a thorough analysis by the leader in consensus forecasts of leading industry analysis and analysis of the pharmaceutical and biotechnology healthcare sector, EvaluatePharma. US spend on prescription drugs is set to grow strongly following the unprecedented 50 new drugs approved in America during 2014. Worldwide prescription drug sales are expected to reach almost $1T dollars by 2020 (CAGR: 4.8% between 2014 and 2020). The value of M&A transactions almost doubled to $116bn in 2014; the number of transactions increased after two years of decline.
Encouragingly for drug developers, despite the increased number of drugs approved, up from 35 in 2013, the quality of the new drugs did not slip. Eight of the top ten new drugs approved in 2014 are forecast to have sales of more than $1bn five years after launch, and included the first crop of PD-1 drugs approved in the year. Sales averaged across all 50 came in at $528m, slightly up on the $522m achieved last year. This jump in productivity has interestingly come at a time when R&D spend continues to be closely scrutinized by large Pharma groups. This year’s World Preview shows prescription drug sales are set to advance at almost 5% a year until 2020. Continued confidence in the sector is being driven by a number of positive fundamentals including the recent increase in R&D productivity, which has resulted in a big hike in drug approvals, and the emergence of breakout drugs such as Gilead’s Sovaldi franchise. Excitement surrounding new products including Merck & Co’s Keytruda, Bristol-Myers Squibb’s Opdivo and antiPCSK9s from Amgen and Sanofi should ensure the sales momentum continues. For more on EvaluatePharma's outlook to 2020 click here There you have it everyone. Start your own research now, and remember to use sound money management and trading discipline. Always book a profit when you can and never risk more than you can afford to lose. The OTC markets, like all exchanges, can move quick and be volatile. Always do your due diligence.
|
|
Sincerely,
Fortune Stock Alerts
|
|
Dear Reader: Sadly, there is no magic formula to getting rich. Success in the stock market can only come from the best prospects for price appreciation and can only be achieved through proper and rigorous research and analysis.
The opinions in this e-newsletter are just that, opinions of the authors. Information contained herein, while believed to be correct, is not guaranteed as accurate. Almost all the stocks I discuss in my newsletter I have been paid to talk about since that is the way this site makes money. I will always include any compensation I have or expect to receive if that happens to make a difference to you. Investing in stocks (especially penny stocks) involves high risks and you can lose all of your money, so do not invest with money you cannot afford to lose.
The below Disclaimer is to be read in full:
Disclaimer
By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. FortuneStockAlerts.com are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damag es, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. FortuneStockAlerts.com does not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on EOD or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices.
Release of Liability: Through use of this website viewing or using you agree to hold FortuneStockAlerts.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. The information contained herein is based on sources, which we believe to be reliable, but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please be advised that FortuneStockAlerts.com is often compensated for issuing press releases, profiles or opinions concerning particular companies, its opinion is therefore biased and you should consider the factor when evaluating FortuneStockAlerts.com statements regarding a company. FortuneStockAlerts.com officers and directors do not own any shares of the mentioned company(s). When FortuneStockAlerts.com receives f ree or restricted trading shares as a compensation for a profiled company, FortuneStockAlerts.com may sell part or all of such shares during the period in which FortuneStockAlerts.com is performing such services. FortuneStockAlerts.com will disclose how many and what type of shares we have been compensated if we do receive shares or buy shares of a profiled company. FortuneStockAlerts.com will also disclose any compensation.
FortuneStockAlerts.com, which is fully owned and operated by Freedom Ventures, LLC, has been compensated up to Five Thousand Dollars Cash via bank wire by a third party, StockMister LLC, for this one day marketing and awareness campaign on MEDH ending on June 2nd, 2016. This compensation/expected compensation is a major conflict of interest in our ability to be unbiased. Therefore, this newsletter should be read as a commercial advertisement only. The third party, company, or their affiliates will liquidate shares, which has the potential to hurt share prices. Notice of Stock Price Movements and Volatility Viewers of this newsletter should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. A company's actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our we bsite is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct.
FortuneStockAlerts.com encourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and FortuneStockAlerts.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Neither FortuneStockAlerts.com, nor any of its affiliates are not registered investment advisors or a broker dealer. Please read our FULL Disclaimer at FortuneStockAlerts.com/Disclaimer.
|
|
|